Leuprolide Acetate 11.25 Mg Injection

Leuprolide Acetate 11.25 Mg Injection works through a biphasic response. During the first week of treatment, there is a transient increase in hormone levels (the “flare” effect). Continued treatment leads to a profound down-regulation of receptors, resulting in suppressed testosterone and estrogen levels within 2 to 4 weeks.

Key Clinical Benefits

• Quarterly Convenience: The 11.25 mg strength is a 3-month depot, reducing the frequency of clinic visits compared to monthly injections.

• Tumor Suppression: Significantly lowers Prostate-Specific Antigen (PSA) levels and shrinks androgen-dependent prostate tumors.

• Pain Management: Highly effective at reducing pelvic pain and thinning the endometrial lining in women with severe endometriosis.

• Fibroid Reduction: Used preoperatively to shrink uterine fibroids and improve hematologic status (reduce anemia) before surgery.

Administration & Clinical Protocols

1. Professional Use Only: Must be administered as an Intramuscular (IM) or Subcutaneous (SC) injection by a healthcare professional.

2. Reconstitution: The lyophilized powder must be mixed with the provided diluent immediately before use. Shake well to ensure a uniform suspension.

3. Site Rotation: Injection sites should be rotated periodically to maintain optimal absorption and skin health.

4. Flare Prevention: In prostate cancer patients, an anti-androgen is often prescribed during the first few weeks to prevent the “testosterone flare” symptoms.

5. Storage: Store at room temperature, 15°C to 30°C (59°F to 86°F). Do not freeze the pre-filled syringe or vial.